🎉 M&A multiples are live!
Check it out!

bluebird bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for bluebird bio and similar public comparables like Galapagos, Julphar, and Pharming.

bluebird bio Overview

About bluebird bio

bluebird bio Inc is a  biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.


Founded

1992

HQ

United States of America
Employees

248

Website

bluebirdbio.com

Financials

LTM Revenue $131M

LTM EBITDA -$213M

EV

$343M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

bluebird bio Financials

bluebird bio has a last 12-month revenue of $131M and a last 12-month EBITDA of -$213M.

In the most recent fiscal year, bluebird bio achieved revenue of $83.8M and an EBITDA of -$157M.

bluebird bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See bluebird bio valuation multiples based on analyst estimates

bluebird bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $29.5M $83.8M XXX XXX XXX
Gross Profit -$6.5M -$4.0M XXX XXX XXX
Gross Margin -22% -5% XXX XXX XXX
EBITDA -$167M -$157M XXX XXX XXX
EBITDA Margin -567% -187% XXX XXX XXX
Net Profit -$267M -$212M XXX XXX XXX
Net Margin -904% -253% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

bluebird bio Stock Performance

As of April 15, 2025, bluebird bio's stock price is $5.

bluebird bio has current market cap of $46.6M, and EV of $343M.

See bluebird bio trading valuation data

bluebird bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$343M $46.6M XXX XXX XXX XXX $-21.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

bluebird bio Valuation Multiples

As of April 15, 2025, bluebird bio has market cap of $46.6M and EV of $343M.

bluebird bio's trades at 2.6x LTM EV/Revenue multiple, and -1.6x LTM EBITDA.

Analysts estimate bluebird bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for bluebird bio and 10K+ public comps

bluebird bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $343M XXX XXX XXX
EV/Revenue 4.1x XXX XXX XXX
EV/EBITDA -2.2x XXX XXX XXX
P/E -0.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get bluebird bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

bluebird bio Valuation Multiples

bluebird bio's NTM/LTM revenue growth is 131%

bluebird bio's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, bluebird bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate bluebird bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for bluebird bio and other 10K+ public comps

bluebird bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 184% XXX XXX XXX XXX
EBITDA Margin -187% XXX XXX XXX XXX
EBITDA Growth -6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -56% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 112% XXX XXX XXX XXX
Opex to Revenue 313% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

bluebird bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

bluebird bio M&A and Investment Activity

bluebird bio acquired  XXX companies to date.

Last acquisition by bluebird bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . bluebird bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by bluebird bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About bluebird bio

When was bluebird bio founded? bluebird bio was founded in 1992.
Where is bluebird bio headquartered? bluebird bio is headquartered in United States of America.
How many employees does bluebird bio have? As of today, bluebird bio has 248 employees.
Who is the CEO of bluebird bio? bluebird bio's CEO is Mr. Andrew Obenshain.
Is bluebird bio publicy listed? Yes, bluebird bio is a public company listed on NAS.
What is the stock symbol of bluebird bio? bluebird bio trades under BLUE ticker.
When did bluebird bio go public? bluebird bio went public in 2013.
Who are competitors of bluebird bio? Similar companies to bluebird bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of bluebird bio? bluebird bio's current market cap is $46.6M
What is the current revenue of bluebird bio? bluebird bio's last 12-month revenue is $131M.
What is the current EBITDA of bluebird bio? bluebird bio's last 12-month EBITDA is -$213M.
What is the current EV/Revenue multiple of bluebird bio? Current revenue multiple of bluebird bio is 2.6x.
What is the current EV/EBITDA multiple of bluebird bio? Current EBITDA multiple of bluebird bio is -1.6x.
What is the current revenue growth of bluebird bio? bluebird bio revenue growth between 2023 and 2024 was 184%.
Is bluebird bio profitable? Yes, bluebird bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.